CO2019004003A2 - Composiciones y anticuerpos anti-lag-3 - Google Patents

Composiciones y anticuerpos anti-lag-3

Info

Publication number
CO2019004003A2
CO2019004003A2 CONC2019/0004003A CO2019004003A CO2019004003A2 CO 2019004003 A2 CO2019004003 A2 CO 2019004003A2 CO 2019004003 A CO2019004003 A CO 2019004003A CO 2019004003 A2 CO2019004003 A2 CO 2019004003A2
Authority
CO
Colombia
Prior art keywords
lag
antibodies
compositions
cancer
diseases
Prior art date
Application number
CONC2019/0004003A
Other languages
English (en)
Inventor
Thomas Bouquin
Torben Gjetting
Gunther Roland Galler
Michael Monrad Grandal
Mikkel Wandahl Pedersen
Vikram Kjøller Bhatia
Camilla Fröhlich
Michael Kragh
Ivan David Horak
Original Assignee
Symphogen As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Symphogen As filed Critical Symphogen As
Publication of CO2019004003A2 publication Critical patent/CO2019004003A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Abstract

Esta invención se refiere a anticuerpos anti-LAG-3 y métodos para usarlos en el tratamiento de enfermedades y afecciones que se benefician de modular la actividad LAG-3, por ejemplo, cáncer.
CONC2019/0004003A 2016-10-13 2019-04-23 Composiciones y anticuerpos anti-lag-3 CO2019004003A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662407678P 2016-10-13 2016-10-13
PCT/EP2017/076188 WO2018069500A2 (en) 2016-10-13 2017-10-13 Anti-lag-3 antibodies and compositions

Publications (1)

Publication Number Publication Date
CO2019004003A2 true CO2019004003A2 (es) 2019-04-30

Family

ID=60201531

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2019/0004003A CO2019004003A2 (es) 2016-10-13 2019-04-23 Composiciones y anticuerpos anti-lag-3

Country Status (22)

Country Link
US (3) US11390676B2 (es)
EP (1) EP3526255A2 (es)
JP (2) JP7212821B2 (es)
KR (2) KR20230136711A (es)
CN (4) CN117567623A (es)
AU (1) AU2017342071A1 (es)
BR (1) BR112019006876A2 (es)
CA (1) CA3039140A1 (es)
CL (1) CL2019000979A1 (es)
CO (1) CO2019004003A2 (es)
EA (1) EA201990912A1 (es)
IL (1) IL265844B2 (es)
MA (1) MA46525A (es)
MX (1) MX2019004241A (es)
PE (1) PE20190911A1 (es)
PH (1) PH12019500668A1 (es)
RU (1) RU2755503C2 (es)
SG (1) SG10201912940WA (es)
TN (1) TN2019000099A1 (es)
TW (1) TWI784976B (es)
UA (1) UA127050C2 (es)
WO (1) WO2018069500A2 (es)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202246349A (zh) 2016-10-11 2022-12-01 美商艾吉納斯公司 抗ｌａｇ－３抗體及其使用方法
CN117567623A (zh) * 2016-10-13 2024-02-20 正大天晴药业集团股份有限公司 抗lag-3抗体及组合物
JP2020513009A (ja) 2017-04-05 2020-04-30 シムフォゲン・アクティーゼルスカブＳｙｍｐｈｏｇｅｎ Ａ／Ｓ Ｐｄ−１、ｔｉｍ−３、およびｌａｇ−３を標的とする併用治療
KR20200010500A (ko) 2017-05-30 2020-01-30 브리스톨-마이어스 스큅 컴퍼니 항-lag-3 항체, pd-1 경로 억제제, 및 면역요법제의 조합을 포함하는 조성물
CA3065304A1 (en) 2017-05-30 2018-12-06 Bristol-Myers Squibb Company Compositions comprising an anti-lag-3 antibody or an anti-lag-3 antibody and an anti-pd-1 or anti-pd-l1 antibody
JP2020522691A (ja) 2017-05-30 2020-07-30 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｌａｇ−３陽性腫瘍の処置
CN110204614B (zh) * 2018-02-28 2022-07-12 广州誉衡生物科技有限公司 抗人lag-3单克隆抗体及其制备方法和用途
US11795221B2 (en) * 2018-02-28 2023-10-24 WuXi Biologics Ireland Limited Monoclonal antibody against human LAG-3, method for preparing the same, and use thereof
MX2020011588A (es) * 2018-05-03 2020-12-07 Shanghai Epimab Biotherapeutics Co Ltd Anticuerpos de alta afinidad a pd-1 y lag-3 y proteinas de union bispecificas preparadas a partir de las mismas.
CN110615840A (zh) * 2018-06-19 2019-12-27 信达生物制药(苏州)有限公司 全人源的抗lag-3抗体及其应用
BR112021000511A2 (pt) 2018-07-26 2021-04-06 Bristol-Myers Squibb Company Terapia de combinação de lag-3 para o tratamento de câncer
AU2019361124A1 (en) 2018-10-19 2021-06-03 Bristol-Myers Squibb Company Combination therapy for melanoma
CN111620949A (zh) * 2019-02-28 2020-09-04 三生国健药业（上海）股份有限公司 结合人lag-3的抗体、其制备方法和用途
JP2022532490A (ja) 2019-05-13 2022-07-15 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 癌の治療における有効性の増強のためのｐｄ－１阻害剤とｌａｇ－３阻害剤の組み合わせ
KR20220016157A (ko) 2019-05-30 2022-02-08 브리스톨-마이어스 스큅 컴퍼니 세포 국재화 시그너쳐 및 조합 요법
US20220363760A1 (en) 2019-05-30 2022-11-17 Bristol-Myers Squibb Company Multi-tumor gene signature for suitability to immuno-oncology therapy
WO2020243568A1 (en) 2019-05-30 2020-12-03 Bristol-Myers Squibb Company Methods of identifying a subject suitable for an immuno-oncology (i-o) therapy
IT201900011676A1 (it) * 2019-07-12 2021-01-12 St Superiore Di Sanita Anticorpo ricombinante umano contro il recettore di membrana LAG3, suoi usi medici e diagnostici.
WO2021024020A1 (en) 2019-08-06 2021-02-11 Astellas Pharma Inc. Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
EP4025605A1 (en) * 2019-09-06 2022-07-13 Symphogen A/S Anti-cd73 antibodies
WO2021055994A1 (en) 2019-09-22 2021-03-25 Bristol-Myers Squibb Company Quantitative spatial profiling for lag-3 antagonist therapy
WO2021092221A1 (en) 2019-11-06 2021-05-14 Bristol-Myers Squibb Company Methods of identifying a subject with a tumor suitable for a checkpoint inhibitor therapy
WO2021092220A1 (en) 2019-11-06 2021-05-14 Bristol-Myers Squibb Company Methods of identifying a subject with a tumor suitable for a checkpoint inhibitor therapy
JP2022553851A (ja) 2019-11-08 2022-12-26 ブリストル－マイヤーズ スクイブ カンパニー 黒色腫の処置のためのｌａｇ－３アンタゴニスト
CN115362167A (zh) 2020-02-06 2022-11-18 百时美施贵宝公司 Il-10及其用途
CN114605544B (zh) * 2020-06-05 2023-08-01 北京天广实生物技术股份有限公司 Lag3抗体及其用途
CA3182579A1 (en) 2020-07-07 2022-01-13 Ugur Sahin Therapeutic rna for hpv-positive cancer
BR112023003427A2 (pt) 2020-08-28 2023-03-21 Bristol Myers Squibb Co Terapia com antagonista de lag-3 para carcinoma hepatocelular
AU2021334361A1 (en) 2020-08-31 2023-05-11 Bristol-Myers Squibb Company Cell localization signature and immunotherapy
EP4232019A1 (en) 2020-10-23 2023-08-30 Bristol-Myers Squibb Company Lag-3 antagonist therapy for lung cancer
WO2022120179A1 (en) 2020-12-03 2022-06-09 Bristol-Myers Squibb Company Multi-tumor gene signatures and uses thereof
TW202245808A (zh) 2020-12-21 2022-12-01 德商拜恩迪克公司 用於治療癌症之治療性ｒｎａ
WO2022135667A1 (en) 2020-12-21 2022-06-30 BioNTech SE Therapeutic rna for treating cancer
WO2022135666A1 (en) 2020-12-21 2022-06-30 BioNTech SE Treatment schedule for cytokine proteins
JP2024501029A (ja) 2020-12-28 2024-01-10 ブリストル－マイヤーズ スクイブ カンパニー Ｐｄ１／ｐｄ－ｌ１抗体の皮下投与
AU2021411486A1 (en) 2020-12-28 2023-06-29 Bristol-Myers Squibb Company Antibody compositions and methods of use thereof
WO2022212400A1 (en) 2021-03-29 2022-10-06 Juno Therapeutics, Inc. Methods for dosing and treatment with a combination of a checkpoint inhibitor therapy and a car t cell therapy
WO2022240741A1 (en) 2021-05-12 2022-11-17 Dana-Farber Cancer Institute, Inc. Lag3 and gal3 inhibitory agents, xbp1, cs1, and cd138 peptides, and methods of use thereof
AU2022312698A1 (en) 2021-07-13 2024-01-25 BioNTech SE Multispecific binding agents against cd40 and cd137 in combination therapy for cancer
AU2022314734A1 (en) 2021-07-19 2024-02-08 Regeneron Pharmaceuticals, Inc. Il12 receptor agonists and methods of use thereof
WO2023022965A2 (en) 2021-08-16 2023-02-23 Regeneron Pharmaceuticals, Inc. Novel il27 receptor agonists and methods of use thereof
TW202333802A (zh) 2021-10-11 2023-09-01 德商拜恩迪克公司 用於肺癌之治療性rna(二)
WO2023077090A1 (en) 2021-10-29 2023-05-04 Bristol-Myers Squibb Company Lag-3 antagonist therapy for hematological cancer
WO2023147371A1 (en) 2022-01-26 2023-08-03 Bristol-Myers Squibb Company Combination therapy for hepatocellular carcinoma
WO2023164638A1 (en) 2022-02-25 2023-08-31 Bristol-Myers Squibb Company Combination therapy for colorectal carcinoma
WO2023168404A1 (en) 2022-03-04 2023-09-07 Bristol-Myers Squibb Company Methods of treating a tumor
WO2023170606A1 (en) 2022-03-08 2023-09-14 Alentis Therapeutics Ag Use of anti-claudin-1 antibodies to increase t cell availability
WO2023178329A1 (en) 2022-03-18 2023-09-21 Bristol-Myers Squibb Company Methods of isolating polypeptides
WO2023220647A1 (en) 2022-05-11 2023-11-16 Regeneron Pharmaceuticals, Inc. Multispecific binding molecule proproteins and uses thereof
US20230382969A1 (en) 2022-05-27 2023-11-30 Regeneron Pharmaceuticals, Inc. Interleukin-2 proproteins and uses thereof
WO2023235847A1 (en) 2022-06-02 2023-12-07 Bristol-Myers Squibb Company Antibody compositions and methods of use thereof
US20230391844A1 (en) 2022-06-04 2023-12-07 Regeneron Pharmaceuticals, Inc. Interleukin-2 proproteins and uses thereof
WO2024040247A1 (en) 2022-08-18 2024-02-22 Regeneron Pharmaceuticals, Inc. Interferon proproteins and uses thereof
US20240067691A1 (en) 2022-08-18 2024-02-29 Regeneron Pharmaceuticals, Inc. Interferon receptor agonists and uses thereof
CN117159703B (zh) * 2023-11-02 2024-04-02 正大天晴(广州)医药有限公司 含抗lag-3抗体的药物组合物及其用途

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
US4740461A (en) 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
WO1986005807A1 (en) 1985-04-01 1986-10-09 Celltech Limited Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4959455A (en) 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
MX9605365A (es) * 1994-05-06 1997-12-31 Roussy Inst Gustave Fracciones polipeptidicas solubles de la proteina lag-3; procedimiento de produccion; composicion terapeutica y anticuerpos ant-idiotipo.
EP1105427A2 (en) 1998-08-17 2001-06-13 Abgenix, Inc. Generation of modified molecules with increased serum half-lives
US6517529B1 (en) 1999-11-24 2003-02-11 Radius International Limited Partnership Hemodialysis catheter
ES2528794T3 (es) 2000-04-11 2015-02-12 Genentech, Inc. Anticuerpos multivalentes y usos de los mismos
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
EP1987839A1 (en) * 2007-04-30 2008-11-05 I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
US9244059B2 (en) * 2007-04-30 2016-01-26 Immutep Parc Club Orsay Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
MX2012012441A (es) * 2010-05-04 2013-02-26 Merrimack Pharmaceuticals Inc Anticuerpos contra el receptor del factor de crecimiento epidermico (egfr) y usos de los mismos.
AR091649A1 (es) 2012-07-02 2015-02-18 Bristol Myers Squibb Co Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos
JO3532B1 (ar) * 2013-03-13 2020-07-05 Regeneron Pharma الأجسام المضادة لمضاد انترلوكين-33 واستعمالاتها
AU2014230741B2 (en) * 2013-03-15 2017-04-13 Glaxosmithkline Intellectual Property Development Limited Anti-LAG-3 binding proteins
EP3178849B1 (en) 2013-09-20 2019-03-20 Bristol-Myers Squibb Company Combination of anti-lag-3 antibodies and anti-pd-1 antibodies to treat tumors
EP3049442A4 (en) 2013-09-26 2017-06-28 Costim Pharmaceuticals Inc. Methods for treating hematologic cancers
CN106103484B (zh) * 2014-03-14 2021-08-20 诺华股份有限公司 针对lag-3的抗体分子及其用途
JO3663B1 (ar) 2014-08-19 2020-08-27 Merck Sharp & Dohme الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
MA41463A (fr) 2015-02-03 2017-12-12 Anaptysbio Inc Anticorps dirigés contre le gène d'activation 3 des lymphocytes (lag-3)
TWI773646B (zh) 2015-06-08 2022-08-11 美商宏觀基因股份有限公司 結合lag-3的分子和其使用方法
AR108516A1 (es) 2016-05-18 2018-08-29 Boehringer Ingelheim Int Moléculas de anticuerpo anti-pd1 y anti-lag3 para el tratamiento del cáncer
CN117567623A (zh) * 2016-10-13 2024-02-20 正大天晴药业集团股份有限公司 抗lag-3抗体及组合物
JP2020513009A (ja) 2017-04-05 2020-04-30 シムフォゲン・アクティーゼルスカブＳｙｍｐｈｏｇｅｎ Ａ／Ｓ Ｐｄ−１、ｔｉｍ−３、およびｌａｇ−３を標的とする併用治療

Also Published As

Publication number Publication date
CN117567622A (zh) 2024-02-20
CN110062766A (zh) 2019-07-26
CN117567623A (zh) 2024-02-20
JP2020500006A (ja) 2020-01-09
WO2018069500A3 (en) 2019-01-03
PH12019500668A1 (en) 2019-07-24
RU2755503C2 (ru) 2021-09-16
EP3526255A2 (en) 2019-08-21
US11390676B2 (en) 2022-07-19
MX2019004241A (es) 2019-08-05
CA3039140A1 (en) 2018-04-19
PE20190911A1 (es) 2019-06-26
TWI784976B (zh) 2022-12-01
US11834503B2 (en) 2023-12-05
RU2019113790A3 (es) 2021-02-01
JP7212821B2 (ja) 2023-01-26
KR102583190B1 (ko) 2023-09-26
TN2019000099A1 (en) 2020-07-15
CL2019000979A1 (es) 2019-06-21
EA201990912A1 (ru) 2019-10-31
WO2018069500A2 (en) 2018-04-19
JP2023027199A (ja) 2023-03-01
KR20190059958A (ko) 2019-05-31
US20220363757A1 (en) 2022-11-17
MA46525A (fr) 2019-08-21
BR112019006876A2 (pt) 2019-06-25
US20220056126A1 (en) 2022-02-24
CN110062766B (zh) 2023-12-15
CN117567621A (zh) 2024-02-20
KR20230136711A (ko) 2023-09-26
UA127050C2 (uk) 2023-03-29
SG10201912940WA (en) 2020-02-27
AU2017342071A1 (en) 2019-04-18
IL265844B1 (en) 2023-11-01
TW201827462A (zh) 2018-08-01
IL265844B2 (en) 2024-03-01
IL265844A (en) 2019-06-30
US20240052032A1 (en) 2024-02-15
RU2019113790A (ru) 2020-11-13

Similar Documents

Publication Publication Date Title
CO2019004003A2 (es) Composiciones y anticuerpos anti-lag-3
CO2018003500A2 (es) Anticuerpos anti-pd-1 y composiciones
CL2018002359A1 (es) Métodos para usar agonistas de fxr
CL2018001152A1 (es) Composiciones y métodos para el tratamiento del cáncer
SV2018005709A (es) 3-azabiciclo[3.1.0]hexanos sustituidos como inhibidores de cetohexoquinasa
PE20180243A1 (es) Composiciones que comprenden cepas bacterianas
SV2017005420A (es) Composiciones y métodos de uso para tratar trastornos metabólicos
CL2018002814A1 (es) Composiciones y metodos para el tratamiento de heridas, trastornos, y enfermedades de la piel.
CL2016001871A1 (es) Anticuerpos humanos para pd-1
NI201600071A (es) Compuestos de inhibidor de autotaxina
CL2019002368A1 (es) Composiciones y métodos para el tratamiento de cáncer.
CO2017007121A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
MX2019001471A (es) Anticuerpos anti-siglec-7 para el tratamiento del cancer.
SG10201808940WA (en) Nox inhibitor and nfкb inhibitor containing methoxyflavone
CY1123290T1 (el) Ενωσεις και μεθοδοι χρησης
AR115583A1 (es) Composiciones y métodos para el tratamiento de las enfermedades y trastornos del hígado
CL2018000597A1 (es) Métodos para tratar enfermedades inflamatorias
CL2019002251A1 (es) Anticuerpos contra triptasa, composiciones de estos y usos de estos.
ECSP19090645A (es) Composición que comprende manosa oligosacárido y proceso para realizarla y uso de esta
MX2019013808A (es) Compuestos desestabilizadores de microtubulina para usarse en el tratamiento del cancer.
BR112018000776A2 (pt) métodos para tratamento de câncer usando apilimod
CL2019002427A1 (es) Inhibición de smarca2 para el tratamiento de cáncer.
NI201600070A (es) Inhibidores tetracíclicos de autotaxina
CO2022002622A2 (es) Anticuerpos anti-cd73 y composiciones
CL2017000595A1 (es) Anticuerpo monoclonal humanizado que inhibe la actividad enzimática de la lipasa endotelial vascular